InvestSMART

Nyrada Inc (ASX:NYR)

ALERT: Price-sensitive ASX Announcement for NYR
Current share price for NYR : $0.675 -0.065 (-8.78%)+
Announcement
Release
21 Aug 2026 8:50AM
Price at Release
$0.740
Full Release
download
Summary
Nyrada Inc conducted a preclinical study to evaluate the efficacy of their drug Xolatryp in protecting cardiac function against doxorubicin-induced cardiotoxicity. The study demonstrated that Xolatryp significantly attenuated the decline in cardiac function caused by doxorubicin, showing comparable efficacy to dexrazoxane, an existing cardioprotective agent. Xolatryp provided sustained protection across multiple echocardiographic measures over five weeks, confirming its cardioprotective potential. Additionally, Xolatryp has shown anti-tumour activity when used alone and in combination with doxorubicin, highlighting its potential as an adjunct to enhance anthracycline therapy. Nyrada plans to explore further clinical trials to establish Xolatryp's role in oncology.
Key Points
  • Xolatryp significantly protected cardiac function against doxorubicin-induced cardiotoxicity.
  • The magnitude of functional protection was comparable to dexrazoxane.
  • Xolatryp provided sustained protection over five weeks in the study.
  • Xolatryp showed anti-tumour activity alone and synergistically with doxorubicin.
  • Nyrada plans further clinical trials to explore Xolatryp's potential in oncology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.